Los Angeles Capital Management
EPZM

Los Angeles Capital Management’s Epizyme, Inc EPZM Stock Holding History

Los Angeles Capital Management’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-91,173
Closed -$105K – 1525
2022
Q1 		$105K Buy
+91,173
New +$149K ﹤0.01% 1386
2020
Q3 		– Sell
-12,005
Closed -$193K – 1556
2020
Q2 		$193K Buy
+12,005
New +$210K ﹤0.01% 1403

Other funds holding EPZM

RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Los Angeles Capital Management's EPZM Position: Q2 2022 in Review

Los Angeles Capital Management sold out of Epizyme, Inc (EPZM) in Q2 2022, closing a stake of 91,173 shares — an estimated $105K sold.

Los Angeles Capital Management first reported a position in EPZM in Q2 2020 and held it in 2 quarters. The position peaked at $193K in Q2 2020. 93 funds tracked by Wall St. Rank hold EPZM as of Q2 2022.

  • Los Angeles Capital Management reported no remaining Epizyme, Inc position as of Q2 2022 after selling out during the quarter.
  • Los Angeles Capital Management sold 91,173 Epizyme, Inc shares in Q2 2022, an estimated $105K.
  • Los Angeles Capital Management first reported a position in Epizyme, Inc in Q2 2020 and held it in 2 quarters.
  • Los Angeles Capital Management's Epizyme, Inc position peaked at $193K in Q2 2020.
  • 93 funds tracked by Wall St. Rank held Epizyme, Inc as of Q2 2022.

Based on Los Angeles Capital Management's 13F filing for Q2 2022, filed 5 Aug 2022.